Opus Genetics (NASDAQ:IRD – Get Free Report) is anticipated to issue its quarterly earnings data on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $11.10 million for the quarter.
Opus Genetics Stock Up 2.9 %
NASDAQ:IRD opened at $1.07 on Thursday. The company has a 50 day simple moving average of $1.16. The company has a market capitalization of $33.78 million, a price-to-earnings ratio of -0.98 and a beta of 0.16. Opus Genetics has a 12-month low of $0.81 and a 12-month high of $2.65.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Opus Genetics in a research note on Wednesday, February 19th.
Insider Transactions at Opus Genetics
In related news, CEO George Magrath purchased 100,000 shares of Opus Genetics stock in a transaction that occurred on Thursday, December 26th. The shares were acquired at an average price of $0.98 per share, with a total value of $98,000.00. Following the completion of the transaction, the chief executive officer now directly owns 599,150 shares of the company’s stock, valued at $587,167. This represents a 20.03 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is owned by corporate insiders.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Further Reading
- Five stocks we like better than Opus Genetics
- NYSE Stocks Give Investors a Variety of Quality Options
- Buffett’s on the Sidelines – Should You Follow?
- Best Aerospace Stocks Investing
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- There Are Different Types of Stock To Invest In
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.